

SCIENTIFIC PROGRAM

Sunday, 13 June

08.00–09.00 Fennia I+II	Breakfast meeting: Prevention and treatment of osteoporosis (1) Sponsored by Leiras	<i>Roger Francis, UK</i>
09.00–09.05 Europaea	Opening remarks	<i>Olavi Ylikorkala, Finland</i>
09.05–09.50 Europaea	Plenary: Reproduction-related glycoprotein secretion in fertilisation and implantation revisited: Clinical implications (2) Chair: Peter Hornnes, Denmark	<i>Markku Seppälä, Finland</i>
09.50–09.55 Europaea	Young Investigator Prize	
Coffee break & Exhibition		
10.30–12.15 Europaea	Symposium: Present status of infertility and its treatment Chairs: Osk Ingvarsdottir, Iceland and Arne Sunde, Norway	
	One embryo transfer is clinically appropriate (3)	<i>Aila Tiitinen, Finland</i>
	Cross-talk between genetics and IVF (4)	<i>Jakob Ingerslev, Denmark</i>
	Longterm outcome of children born by ART (5)	<i>Ulla-Britt Wennerholm, Sweden</i>
	Legal issues in ART in Nordic countries (6)	<i>Arne Sunde, Norway</i>
10.30–12.15 Fennia I	Free communications: Preeclampsia Chairs: Jens Gudmundsson, Iceland and Hannele Laivuori, Finland	
	Association for preeclampsia on chromosome 2p25 (7)	<i>Hannele Laivuori, Finland</i>
	Tumor suppressor and growth regulatory genes are over-expressed in severe early-onset preeclampsia. An array study on case-specific human preeclamptic placental tissue (8)	<i>Annaleena Heikkilä, Finland</i>
	Does ISG12 play a role in preeclampsia? (9)	<i>Camilla Jensenius Skovhus Kronborg, Denmark</i>
	Paternity change and the recurrence risk of familial hypertensive disorder in pregnancy (10)	<i>Sigrun Hjartardóttir, Iceland</i>
	Acute atherosclerosis: Not only associated with preeclampsia (11)	<i>Nina Kittelsen Harsem, Norway</i>
	Is there an association between the intake of vitamin C and preeclampsia? A prospective study among 42,295 women (12)	<i>Åse Kathrine Klemmensen, Denmark</i>
	Effect of ASA on the risk of gestational hypertension and prostanoïd synthesis in pregnant women screened by Doppler ultrasound (13)	<i>Merja Vainio, Finland</i>
10.30–12.15 Fennia II	NFOG symposium: "NFOG-NJF going south II" Future collaboration between Nordic gynecologists and midwives in low income countries Chairs: Asta von Frenckell, Finland and Peter Hornnes, Denmark	
	Why and in what way will NFOG and NJF (Nordiske Jordmorförbund) promote international reproductive health? (14)	<i>Peter Hornnes, Denmark</i>
	NFOG-NJF going south II – whom will it benefit? (15)	<i>Birgitta Essén, Sweden</i>
	Research in international reproductive health at Nordic universities during the last two decades (16)	<i>Staffan Bergström, Sweden</i>
	ALARM International – the experiences of an education program to reduce maternal mortality (17)	<i>Kit Dynnes Hansen, Denmark</i> <i>Kenneth Björklund, Sweden</i>
	SAMOUZA-project – toward safer motherhood in the area of AIDS (18)	<i>Kenneth Björklund, Sweden</i>
Lunch & Exhibition (NFOG members meeting at Fennia II)		

13.30–15.15 Europaea	Symposium: More than an effective contraception Mirena® and Yasmin® Chair: Maija Haukkamaa, Finland Sponsored by Schering	
	Opening words	Maija Haukkamaa, Finland
	Use of Mirena® after birth (19)	Jean-Luc Brun, France
	The non-contraceptive benefits of Yasmin® (20)	Diana Mansour, UK
	Long-term contraception for young women (21)	Päivi Pakarinen, Finland
	Panel discussion and take home message	
13.30–15.15 Fennia II	Symposium: Pelvic floor deficiency: lifelong danger for women Chairs: Per Olof Janson, Sweden and Juha Mäkinen, Finland	
	The background to a worldwide success in treatment of female stress incontinence (22)	Carl Gustaf Nilsson, Finland
	The choice of prolaps surgery (23)	Erkki Kujansuu, Finland
	Sphincter lesion after delivery (24)	Karl Møller Bek, Denmark
	How to deal with concomitant incontinence and prolapse (25)	Ellen Borstad, Norway
15.30–16.15 Europaea	Plenary: Molecular genetics in gynecology (26) Chair: Thorbjörn Bäckström, Sweden	Andrea Genazzani, Italy
Coffee break & Exhibition		
16.45–18.30 Europaea	Symposium: Individualised low dose hormone therapy Chair: Andrea Genazzani, Italy Sponsored by Orion	
	Hormone therapy today – where now? (27)	Margaret Rees, UK
	9-year results from a trial in Finnish women – safety and efficacy (28)	Peter van de Weijer, The Netherlands
	9-year results from a trial in Finnish women – effects on bone (29)	Jorma Heikkinen, Finland
	Possible benefits of hormone therapy (30)	Andrea Genazzani, Italy
16.45–18.30 Fennia II	Free communications: Pain and fears in obstetrics Chairs: Unni Kirste, Norway and Thóra Steingrimsdóttir, Iceland	
	Fear of childbirth - does it matter for obstetricians? (31)	Runa Heimstad, Norway
	Cesarean sections and neonatal outcome (32)	Toril Kolås, Norway
	Psychotherapy and relaxation in a group - an effective intervention against fear of childbirth (33)	Terhi Saisto, Finland
	Intimate partner abuse and reproductive health - A Nordic, cross-sectional, multicenter study (34)	Berit Schei, Norway
	Associations between ill health and sexual abuse history among 3,593 gynaecological patients (35)	Malene Hilden, Denmark
	Effects of exposure to selective serotonin re-uptake inhibitors during pregnancy on infant outcome (36)	Tuija Heikkinen, Finland
	Post partum pelvic pain - the 'Pelvic Joint Syndrome' - a diagnostic dilemma (37)	Charlotte Wilken-Jensen, Denmark
09.00–18.00	Poster exhibition on 2nd floor: Endocrinology/Reproductive medicine, no. 201-242, Obstetrics/Perinatology, no. 243-267	

Monday 14 June

08.00–09.00 Fennia I + II	Breakfast meeting: New trends in individualized HRT – Mirena® and Angeliq® Chair: Sven O. Skouby, Denmark Sponsored by Schering Introduction: HRT at present (38) Mirena® in perimenopause (39) Cost-effectiveness of Mirena® in menorrhagia, new 5-year results (40) New progestins – different routes of administration and their use in hormone therapy (41) Panel discussion and take home message	<i>Sven O. Skouby, Denmark</i> <i>Regine Sitruk-Ware, USA</i> <i>Ritva Hurskainen, Finland</i> <i>Regine Sitruk-Ware, USA</i>
09.00–09.45 Europaea	Plenary: Preeclampsia: New insights into the disorder (42) Chair: Reynir Geirsson, Iceland	<i>James Roberts, USA</i>
09.45–10.15	Poster session I: Endocrinology/Reproductive medicine Selected posters from June 13 th Chairs: Ian Milsom, Sweden and Anne-Maria Suikkari, Finland	
10.15–10.20	Prizes for best posters and oral presentations of June 13 th	
	Coffee break & Exhibition	
11.00–12.45 Europaea	Symposium: Preconception or/and prenatal care: prevention or treatment Chairs: Arnar Hauksson, Iceland and Pertti Kirkinen, Finland Diabetes (43) Drug and alcohol abuse (44) Pregnancy, nutrition and exercise (45) Carriers of hereditary disorders (46)	<i>Ulf Hanson, Sweden</i> <i>Erja Halmesmäki, Finland</i> <i>Torun Clausen, Norway</i> <i>Seppo Heinonen, Finland</i>
11.00–12.45 Fennia I	Free communications: Hormones, symptoms and disease Chairs: Marie Bixo, Sweden and Anette Tønnes-Pedersen, Denmark Lack of effect of isolated isoflavonoids on the climacteric symptoms, the vagina and endometrium (47) Apoptosis and expression of p53 in breast tissue during long-term hormone therapy in primates (48) Allopregnanone serum concentrations decrease in response to a low dose of alcohol in the late luteal phase of the menstrual cycle (49) Increased risk of breast cancer with HRT: Highest risk following the use of the continuous combined regimens (50) Nationwide cohort study on cancer incidence among Finnish HRT users 1994–2001 (51) The risk of ischaemic heart disease with hormone therapy among women with early menopause (52) Hormone therapy and cardiovascular disease. A 1.8 million women Danish national cohort study (53)	<i>Eini Nikander, Finland</i> <i>Peter Conner, Sweden</i> <i>Inger Sundström Poromaa, Sweden</i> <i>Claudia Stahlberg, Denmark</i> <i>Heli Kaarina Lyytinen, Finland</i> <i>Ellen Løkkegaard, Denmark</i> <i>Ellen Løkkegaard, Denmark</i>
11.00–12.45 Fennia II	Symposium: Endometriosis, still a challenge in everyday practice Chairs: Margareta Hammarström, Sweden and Britt-Ingjerd Nesheim, Norway Genetics of endometriosis (54) Endometriosis and medical treatment (55) Indications for surgical treatment of endometriosis (56) Does endometriosis predispose to malignancy (57)	<i>Reynir Geirsson, Iceland</i> <i>Mutsuo Ishikawa, Japan</i> <i>Axel Forman, Denmark</i> <i>Agneta Bergqvist, Sweden</i>
12.45–13.45 Fennia II	Lunch meeting: Hysteroscopic endometrial ablation for the 21 st century Chairs: Reijo Raitala, Finland and Minna Maunola, Finland Sponsored by Boston Scientific Introduction Pori centre experience with endometrial ablation for menorrhagia Update on endometrial ablation Questions & Answers – panel Closing	<i>Reijo Raitala, Finland</i> <i>Minna Maunola, Finland</i> <i>Martin Farrugia, UK</i> <i>Reijo Raitala, Finland</i>

Lunch & Exhibition

14.00–15.45 Europaea	Symposium: Postmenopausal hormone therapy today Sponsored by Novo Nordisk Chair: Mette Haase Moen, Norway	
	Cardiovascular effects of hormone therapy – timing is crucial (58)	<i>Tomi Mikkola, Finland</i>
	Bleeding control and endometrium safety with special emphasis on low dose hormone therapy (59)	<i>Lars-Åke Mattson, Sweden</i>
	Breast issues with hormone therapy (60)	<i>Ole-Erik Iversen, Norway</i>
	Anti fracture efficacy of HRT in postmenopausal osteoporosis (61)	<i>Leif Mosekilde, Denmark</i>
14.00–15.45 Fennia II	Symposium: Prediction of intrauterine risks Chairs: Ulf Högberg, Sweden and Pentti Jouppila, Finland	
	IUGR and macrosomia (62)	<i>Karel Marsal, Sweden</i>
	Chromosomal aberrations (63)	<i>Hulda Hjartardottir, Iceland</i>
	Parvo-virus infection (64)	<i>Morten Lebech, Denmark</i>
	Fetal hemodynamics in risk prediction (65)	<i>Torvid Kiserud, Norway</i>
Coffee break & Exhibition		
16.15–17.00 Europaea	Plenary: The diverse priorities of gynecological care in the enlarged EU (66) Chair: Britt Marie Landgren, Sweden	<i>Gunta Lazdane, Latvia</i>
17.00–18.45 Europaea	Symposium: Risk factors and prevention of venous thromboembolism among women Chairs: Jan Maltau, Norway and Charlotte Wilken-Jensen, Denmark	
	Hormonal contraceptives and venous thromboembolism (67)	<i>Øjvind Lidegaard, Denmark</i>
	HRT and SERMs (68)	<i>Sven O. Skouby, Denmark</i>
	Pregnancy and puerperium (69)	<i>Risto Erkkola, Finland</i>
	Traveling and surgical procedures (70)	<i>Margareta Hellgren, Sweden</i>
17.00–18.45 Fennia I	Symposium: Postmenopausal bone: a concern of gynecologists Chairs: Ole-Erik Iversen, Norway and Seppo Saarikoski, Finland	
	Bone is a target of several different hormones (71)	<i>Kalervo Väänänen, Finland</i>
	Biochemical and biophysical detection of increased bone loss and risk of fractures (72)	<i>Marco Gambacciani, Italy</i>
	Prevention of bone loss and fractures by HRT and SERMs (73)	<i>Lars-Åke Mattson, Sweden</i>
	Prevention of bone loss and fractures by nonhormonal agents (74)	<i>Richard Derman, USA</i>
17.00–18.45 Fennia II	Free communications: Clinical gynecology Chairs: Søren Brostrøm, Denmark and Juhani Toivonen, Finland	
	Comparison of two risk of malignancy indexes as a rationale for operative treatment of ovarian tumors (75)	<i>Annika Auranen, Finland</i>
	Autopsy study of the prevalence of adnexal cysts in postmenopausal women (76)	<i>Seth Granberg, Norway</i>
	Medical vs. surgical abortion - comparing efficacy and complications in a partly randomised study (77)	<i>Christina Rørbye, Denmark</i>
	Multiparity predicts failure in medical pregnancy termination (78)	<i>Maarit Niinimäki, Finland</i>
	Can ultrasound replace D & C? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer (79)	<i>Berit Gull, Sweden</i>
	Hysterectomy after endometrial ablation - A national follow up 1996-2003 (80)	<i>Øjvind Lidegaard, Denmark</i>
	Pelvic abscess aspiration under guidance of transvaginal ultrasound (81)	<i>Knut Gjelland, Norway</i>
	Poster exhibition on 2nd floor: Obstetrics/Perinatology, no. 268-321, Oncology/Gynecology, no. 322-335	

Tuesday, 15 June

08.00–09.00 Fennia II	Breakfast meeting: Neuropharmacology of stress urinary incontinence and duloxetine – efficacy and safety of duloxetine (82) Sponsored by Eli Lilly and Boehringer Ingelheim	<i>Søren Brostrøm, Denmark</i>
09.00–10.45 Europaea	Symposium: Molecular basis of obstetrical and gynecological disorders Chairs: Eeva-Marja Rutanen, Finland and Kjell Salvesen, Norway Gene expression and physiological changes of human pregnancy (83) The role of nitric oxide in pregnancy disorders (84) Glucose and insulin axis and its dysfunction in pregnancy disorders (85) Postponement of menopause by gene therapy? (106)	<i>William Dunlop, UK</i> <i>Gautam Chaudhuri, USA</i> <i>Andre van Assche, Belgium</i> <i>Juha Tapanainen, Finland</i>
09.00–10.00 Fennia I	Free communications: Oncology - from epidemiology to prevention Chairs: Oskari Heikinheimo, Finland and Christer Borgfeldt, Sweden Genital human papilloma virus infection in student clinical population (87) A multi-arm trial in cervical cancer control: HPV screening (88) Comparison of HPV test vs. conventional and automation assisted PAP-screening as potential screening tools for preventing cervical cancer (89) Intratutoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma (90)	<i>Jorma Paavonen, Finland</i> <i>Pekka Nieminen, Finland</i> <i>Pekka Nieminen, Finland</i> <i>Marju Dahmoun, Sweden</i>
09.45–10.45 Fennia II	Free communications: Sequela of hormone treatments Chairs: Øjvind Lidegaard, Denmark and Hannu Martikainen, Finland Hormone therapy and female cancers - A 1.8 million women Danish national cohort study (91) Effects of testosterone treatment on insulin sensitivity, body composition and serum lipid profile in postmenopausal women (92) Neurological sequela in assisted reproductive twins: controlled national cohort study (93) Single embryo transfer in frozen embryo transfer cycles – six years' experience (94)	<i>Øjvind Lidegaard, Denmark</i> <i>Hong Zang, Sweden</i> <i>Anja Pinborg, Denmark</i> <i>Leila Unkila-Kallio, Finland</i>
10.00–10.25 Fennia I	Poster session II: Oncology/Gynecology Selected posters from June 14 th Chairs: Pål Wölner-Hanssen, Sweden and Jorma Paavonen, Finland	
10.45–10.50 Europaea	Prizes for best posters and oral presentations of June 14 th	
Coffee break & Exhibition		
11.15–13:00 Europaea	Symposium: Transdermal route – is it more favourable than oral for HRT administration? Chair: Göran Samsioe, Sweden Sponsored by Novartis Women with features of the metabolic syndrome. Is transdermal HT to be preferred? (95) Risk of thromboembolism: Should transdermal route of administration be preferred? (97) Different effects of oral and transdermal HRT on C-reactive protein: Does it have an impact on cardiovascular risk? (98) Low-dose transdermal HRT: - Development from estradiol-patches to combi-patches (99) - Special options to minimize risks (96)	<i>Göran Samsioe, Sweden</i> <i>Sven O. Skouby, Denmark</i> <i>Matti Tikkanen, Finland</i> <i>Alfred O. Mueck, Germany</i>
11.15–11.40 Fennia I	Poster session III: Obstetrics/Perinatology Selected posters from June 13 th and 14 th Chairs: Ulla Ekblad, Finland and Aydin Tekay, Finland	

11.15–13.00 Fennia II	Symposium: Prevention and diagnostics of gynecological cancer Chairs: Seija Grénman, Finland and Kim Toftager-Larsen, Denmark	
	Role of HPV in cervical cancer: From testing to vaccination (100)	<i>Jorma Paavonen, Finland</i>
	Preoperative evaluation of endometrial pathology (101)	<i>Gunnar Kristensen, Norway</i>
	Ultrasound and risk-of-malignancy index in the evaluation of ovarian tumors (102)	<i>Seth Granberg, Sweden</i>
	PET imaging of gynecological malignancies (103)	<i>Heikki Minn, Finland</i>
13.00–13.30 Europaea	Lunch symposium: What is wrong in the Million Women Study? Chair: Olavi Ylikorkala, Finland	<i>Richard Farmer, UK</i>

Lunch & Exhibition

14.00–14.05 Europaea	Prizes for best posters and oral presentations of June 15 th	
14.05–15.50 Europaea	Symposium: Utopia or reality Chairs: Ian Milsom, Sweden and Bent Ottesen, Denmark	
	Transplantation of genital organs (104)	<i>Mats Brännström, Sweden</i>
	Male and female and all those in between (105)	<i>Kenneth Purvis, Norway</i>
	New estrogen/progesterone receptor modulators for future hormonal therapy (86)	<i>Philippe Bouchard, France</i>
	Never too early: Fetal and neonatal education (107)	<i>Risto Näätänen, Finland</i>
14.05–15.50 Fennia I	Free communications: High risk pregnancy Chairs: Tore Henriksen, Norway and Kari Teramo, Finland	
	Poor pregnancy outcome in women with type 2 diabetes (108)	<i>Tine Dalsgaard Clausen, Denmark</i>
	Prediction of diabetes in women with gestational diabetes: Risk for type 1 diabetes is similar to that of type 2 diabetes in fertile age (109)	<i>Ilkka Yrjö Järvelä, Finland</i>
	High amniotic fluid erythropoietin levels are associated with increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies (110)	<i>Kari Teramo, Finland</i>
	Complications to a high pre-pregnancy body mass index in 8.092 Danish pregnancies - the influence of parity (111)	<i>Line Rode, Denmark</i>
	Randomised controlled study of treatment of retained placenta with 100IE intraumbilical oxytocin injection via an infant mucus aspiration tube. (112)	<i>Priya Chauhan, Denmark</i>
	Periodontitis and bacterial vaginosis before pregnancy increase the risk for adverse pregnancy outcome (113)	<i>Tapio Kurki, Finland</i>
	Human chorionic gonadotropin (hCG) during third trimester pregnancy (114)	<i>Greta Edelstam, Sweden</i>
15.50–16.00 Europaea	Closing of the congress	